Trials / Completed
CompletedNCT04760314
A Study of Lebrikizumab (LY3650150) in Combination With Topical Corticosteroids in Japanese Participants With Moderate-to-Severe Atopic Dermatitis
A Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Lebrikizumab When Used in Combination With Topical Corticosteroid Treatment in Japanese Patients With Moderate-to-Severe Atopic Dermatitis
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 286 (actual)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 12 Years
- Healthy volunteers
- Not accepted
Summary
The main purpose of this study is to evaluate the efficacy and safety of lebrikizumab in combination with a topical corticosteroids in Japanese participants with atopic dermatitis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Lebrikizumab | Administered SC |
| DRUG | Placebo | Administered SC |
| DRUG | Topical Corticosteroid | Self-applied |
Timeline
- Start date
- 2021-03-10
- Primary completion
- 2022-07-31
- Completion
- 2023-02-01
- First posted
- 2021-02-18
- Last updated
- 2023-08-23
- Results posted
- 2023-08-23
Locations
37 sites across 1 country: Japan
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04760314. Inclusion in this directory is not an endorsement.